Kurs
+0,46%
Likviditet
0,44 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-11 | 08:00 | Bokslutskommuniké 2025 |
2025-11-03 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-15 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-13 | N/A | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2025-05-12 | N/A | Årsstämma |
2025-05-02 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-11 | - | Bokslutskommuniké 2024 |
2024-11-01 | - | Kvartalsrapport 2024-Q3 |
2024-08-15 | - | Kvartalsrapport 2024-Q2 |
2024-06-26 | - | Årsstämma |
2024-04-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2024-04-15 | - | Kvartalsrapport 2024-Q1 |
2024-02-29 | - | Bokslutskommuniké 2023 |
2023-11-30 | - | Kvartalsrapport 2023-Q3 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2023-05-11 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2023-02-15 | - | Extra Bolagsstämma 2022 |
2022-11-30 | - | Kvartalsrapport 2022-Q3 |
2022-08-31 | - | Kvartalsrapport 2022-Q2 |
2022-05-31 | - | Kvartalsrapport 2022-Q1 |
2022-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2022-05-11 | - | Årsstämma |
2022-02-28 | - | Bokslutskommuniké 2021 |
2021-11-30 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-31 | - | Kvartalsrapport 2021-Q1 |
2021-04-16 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2021-04-15 | - | Årsstämma |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-11-27 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-07-01 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2020-06-30 | - | Årsstämma |
2020-05-29 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Kvartalsrapport 2019-Q3 |
2019-08-30 | - | Kvartalsrapport 2019-Q2 |
2019-06-17 | - | Årsstämma |
2019-04-08 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-16 | - | Kvartalsrapport 2018-Q3 |
2018-08-27 | - | Kvartalsrapport 2018-Q2 |
2018-07-25 | - | Extra Bolagsstämma 2018 |
2018-05-09 | - | Kvartalsrapport 2018-Q1 |
2018-04-19 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2018-04-18 | - | Årsstämma |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-11-23 | - | Kvartalsrapport 2017-Q3 |
2017-08-10 | - | Kvartalsrapport 2017-Q2 |
2017-06-29 | - | Årsstämma |
2017-05-15 | - | Kvartalsrapport 2017-Q1 |
2017-04-24 | - | Extra Bolagsstämma 2017 |
2017-04-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2017-02-14 | - | Bokslutskommuniké 2016 |
2016-11-10 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-10 | - | Kvartalsrapport 2016-Q1 |
2016-04-14 | - | Årsstämma |
2016-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2016-01-28 | - | Bokslutskommuniké 2015 |
2015-10-22 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-04-28 | - | Kvartalsrapport 2015-Q1 |
2015-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2015-03-26 | - | Årsstämma |
2015-01-27 | - | Bokslutskommuniké 2014 |
2014-10-20 | - | Kvartalsrapport 2014-Q3 |
2014-08-19 | - | Kvartalsrapport 2014-Q2 |
2014-06-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2014-06-25 | - | Årsstämma |
2014-04-14 | - | Extra Bolagsstämma 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
The board of BrainCool AB (publ) has established and decided on a new information policy in connection with the listing on the Nasdaq First North Growth Market.
With the new information policy, the company will communicate in English as the first language to the stock market and other stakeholders. Current reports will be designed to better clarify and make visible financial data and product information ant thus make it easier for market players to analyze BrainCool and its development.
Communication from the CEO and the IR function will mainly take place in writing and at capital market days. Answering emails from individual shareholders is not possible due to time constraints, but they are referred to the aforementioned activities.
With more active and better ongoing information and communication to the market, the company will continue to refrain from assessing prospects and giving forecasts. However, this does not change the previous assessment that BrainCool’s ambition is for BrainCool System/IQool to have a turnover of over SEK 100 M in 2025.
Contacts
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se
About Us
About BrainCool AB (publ)
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology.
BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.